Pfizer Inc. (NYSE:PFE) Shares Purchased by Schroder Investment Management Group

Schroder Investment Management Group raised its position in Pfizer Inc. (NYSE:PFE) by 13.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,973,310 shares of the biopharmaceutical company’s stock after acquiring an additional 1,193,722 shares during the quarter. Schroder Investment Management Group’s holdings in Pfizer were worth $264,592,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer in the fourth quarter worth about $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by company insiders.

Pfizer Trading Up 0.8 %

NYSE:PFE opened at $25.20 on Friday. The company has a market capitalization of $142.93 billion, a PE ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The stock’s 50 day moving average price is $26.06 and its 200 day moving average price is $26.92. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the company posted $0.10 EPS. The company’s quarterly revenue was up 24.7% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on PFE. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.